Becton Dickinson Net Income/Loss 2012-2026 | BDX
Becton Dickinson annual/quarterly net income/loss history and growth rate from 2012 to 2026. Net income/loss can be defined as the company's total income or loss before preferred stock dividends, taken from the Income Statement
- Becton Dickinson net income/loss for the quarter ending March 31, 2026 was $382M, a 26.07% increase year-over-year.
- Becton Dickinson net income/loss for the twelve months ending March 31, 2026 was $3.856B, a 6.66% decline year-over-year.
- Becton Dickinson annual net income/loss for 2025 was $1.678B, a 1.58% decline from 2024.
- Becton Dickinson annual net income/loss for 2024 was $1.705B, a 14.89% increase from 2023.
- Becton Dickinson annual net income/loss for 2023 was $1.484B, a 16.58% decline from 2022.
|
Becton Dickinson Annual Net Income/Loss (Millions of US $) |
|
|---|---|
| 2025 | $1,678 |
| 2024 | $1,705 |
| 2023 | $1,484 |
| 2022 | $1,779 |
| 2021 | $2,092 |
| 2020 | $874 |
| 2019 | $1,233 |
| 2018 | $311 |
| 2017 | $1,100 |
| 2016 | $976 |
| 2015 | $695 |
| 2014 | $1,185 |
| 2013 | $1,293 |
| 2012 | $1,170 |
| 2011 | $1,271 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical & Dental Supplies | $43.913B | $21.840B |
| Becton, Dickinson and Company, is a medical technology company engaged principally in the development, manufacture and sale of medical devices, instrument systems and reagents. BD's operations consisted of three business segments: BD Medical, BD Diagnostics and BD Biosciences. The company's organizational structure was realigned to form two principal business segments: BD Medical, BD Life Sciences and BD Interventional. BD Medical: BD Medical's major product lines include needles, syringes and intravenous catheters for medication delivery and generic prefilled injectables. BD Life Sciences - BD Diagnostics provides products for the safe collection and transport of diagnostics specimens to detect a broad range of infectious diseases, healthcare-associated infections and cancer. BD Biosciences produces research and clinical tools that facilitate the study of cells to gain a better understanding of normal and disease processes. With the acquisition of C.R. Bard, BD added a new segment - BD Interventional. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| McKesson (MCK) | United States | $106.025B | 23.03 |
| Cardinal Health (CAH) | United States | $50.715B | 22.43 |
| West Pharmaceutical Services (WST) | United States | $18.493B | 35.19 |
| Straumann Holding AG (SAUHY) | Switzerland | $16.902B | 0.00 |
| Cooper (COO) | United States | $13.894B | 16.52 |
| Align Technology (ALGN) | United States | $12.400B | 21.09 |
| Henry Schein (HSIC) | United States | $8.645B | 15.16 |
| Merit Medical Systems (MMSI) | United States | $4.072B | 19.84 |
| DENTSPLY SIRONA (XRAY) | United States | $2.339B | 7.36 |
| STAAR Surgical (STAA) | United States | $1.309B | 0.00 |
| CONMED (CNMD) | United States | $1.107B | 7.97 |
| Pro-Dex (PDEX) | United States | $0.165B | 19.65 |
| Lifevantage (LFVN) | United States | $0.053B | 5.46 |
| Axe Compute (AGPU) | United States | $0.022B | 0.00 |